H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro^® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck’s newer products, as well as the loss of revenue from Lexapro due to generic competition.

• Lundbeck’s novel multimodal antidepressant, vortioxetine, filed in Europe, Canada and the US - a treatment that may benefit patients with depression who are seeking additional therapeutic options
   
• New Products* increased 100% and constituted 17% of revenue for the third quarter
   
• Onfi^TM revenue in the US is on track to meet expectations and generated revenue of DKK 174 million for the first nine months of 2012
   
• Escitalopram in Japan now holds a market share of 6.1% and for the first nine months generated a royalty of DKK 133 million
   
• Third quarter revenue in the US, excluding Lexapro, increased 44%
   
• Treanda^® launched in Canada, and Azilect^® launched in Thailand, Hong Kong and Australia
   
• Lundbeck is on track to meet financial expectations for 2012
   

Distribution of revenue

*New Products include Xenazine, Sabril, Sycrest, Lexapro (Japan), Onfi and Treanda

In connection with the third quarter report, Lundbeck’s President and CEO Ulf Wiinberg said:
 “We are now one step closer to the launch of our novel antidepressant, vortioxetine, following the filing in Europe, Canada and the very important US market. I am also very pleased with the strategic progress of our new product launches and our geographic expansion.”